STOCK TITAN
  1. Home
  2. News
  3. CHRS

Coherus BioSciences Management to Present at H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

REDWOOD CITY, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will participate at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14 at 10:00 am ET.

An audio webcast of the fireside chat will be available on the investor’s page of the Coherus website at https://investors.coherus.com/upcoming-events. Please access the website prior to the start of the presentation to ensure a timely connection to the webcast. The webcast will be archived on the Coherus website for 30 days.

Marek Ciszewski, J.D.
SVP, Investor Relations
Coherus BioSciences, Inc.
IR@coherus.com


Stock CHRS logo
Coherus Biosciences Inc

NASDAQ:CHRS

CHRS Rankings

#3641 Ranked by Market Cap
#5124 Ranked by Stock Gains
N/A Ranked by Dividends

CHRS Latest News

Apr 24, 2024
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 8, 2024
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
Mar 13, 2024
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
Mar 5, 2024
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
Mar 4, 2024
Coherus Completes Divestiture of Ophthalmology Franchise

CHRS Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
US
Redwood City

About CHRS

coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp